By Judy George, Deputy Managing Editor, MedPage Today
November 12, 2026
For over a decade, the pharmaceutical landscape in Australia was haunted by the silent, steady climb of pregabalin prescriptions. Marketed under the brand name Lyrica, the drug—a gabapentinoid originally designed for epilepsy—had become a "blockbuster" solution for an array of pain conditions. However, this clinical success masked a growing public health crisis: an alarming rise in misuse, addiction, and lethal overdoses.
A landmark retrospective study published in The BMJ has finally provided a blueprint for how this tide might be turned. By analyzing data from 2016 to 2024, researchers led by Rose Cairns, PhD, of the University of Sydney, identified a significant pivot point in the trajectory of pregabalin consumption. Their findings suggest that a combination of media scrutiny, regulatory oversight, and clear safety labeling can act as a powerful brake on the over-prescription of addictive substances.
The Anatomy of the Crisis: A Shift in Prescribing Trends
For years, the prescription of gabapentinoids followed a steep, unchecked upward trajectory. Initially approved for neuropathic pain, postherpetic neuralgia, and fibromyalgia, pregabalin saw its use expand far beyond these narrow indications. In Australia, as in many other high-income nations, the drug became a go-to for various forms of chronic pain, despite limited clinical evidence supporting its efficacy for many of these applications.
The study, which examined a 10% sample of Australia’s Pharmaceutical Benefits Scheme (PBS) data and a 50% sample of calls to the nation’s largest poison control center, revealed a stark reversal. Between 2016 and 2024, researchers tracked over 3.4 million prescriptions and nearly 5,000 overdose-related calls. The data showed that after years of growth, both prescriptions and overdoses dropped significantly—by 25% and 47%, respectively—below projected trends.
This decline was not spontaneous; it was inextricably linked to three major interventions that systematically challenged the "blockbuster" status of the drug.
A Chronology of Intervention
The researchers categorized the decline into three distinct phases, each corresponding to a specific public or regulatory action:
- December 2018 (Media Awareness): The first major dip in prescribing occurred following widespread, high-profile media coverage highlighting the hidden harms and abuse potential of pregabalin. This period served as a wake-up call for both the medical community and the general public.
- April/May 2020 (Regulatory Tightening): The Australian government implemented stricter dispensing rules. By increasing the hurdles for prescribing, regulators effectively curtailed the ease with which the drug could be obtained for off-label use.
- February 2021 (Boxed Warnings): The final, sustained decline followed the introduction of mandatory boxed warnings on product packaging. These warnings provided an unmistakable, standardized alert regarding the risk of respiratory depression and death, particularly when co-administered with opioids.
According to the study, these measures resulted in ongoing monthly reductions in prescriptions of 0.7% and a 1.6% reduction in poison center calls for overdose, signaling that "soft" interventions—when combined with policy—can drive meaningful behavioral change in healthcare.
The "Blockbuster" Mirage: Clinical Utility vs. Commercial Success
The study serves as a harsh critique of how pregabalin reached its peak. In an accompanying editorial, David Juurlink, MD, PhD, of the Sunnybrook Health Sciences Centre in Toronto, noted that the commercial success of pregabalin has "far outstripped its demonstrated clinical utility."
While gabapentinoids are vital for a subset of patients with specific neuropathic conditions, the clinical evidence for their broader use remains thin. Juurlink highlighted that for common complaints like low back pain or sciatica, there is no convincing evidence of benefit. Yet, for years, these conditions served as the primary drivers of prescriptions.
"Although it can provide meaningful relief in some patients," Juurlink wrote, "most do not achieve substantial pain relief." This disconnect between the drug’s reputation and its actual effectiveness underscores a fundamental issue in modern pain management: the reliance on pharmacological "band-aids" for complex, multifactorial pain syndromes.
Global Context: A Universal Challenge
Australia’s experience is not an anomaly. High-income countries globally are struggling with the fallout of the gabapentinoid boom. In the United Kingdom, the situation is particularly dire, with one-third of all substance-use-related deaths now involving a gabapentinoid. Between 2018 and 2022, deaths linked to these drugs in the U.K. more than doubled.
In the United States, the regulatory approach has been fragmented. While the FDA has issued warnings regarding respiratory depression—specifically when gabapentinoids are taken with opioids or other central nervous system depressants—the federal scheduling of these drugs remains inconsistent. Pregabalin is classified as a Schedule V controlled substance, but gabapentin remains unscheduled at the federal level, leading to a patchwork of state-level regulations.
Despite these warnings, the dangerous practice of co-prescribing gabapentinoids with opioids persists, representing a significant risk factor for fatal overdose. The Australian study acts as a clarion call for these countries to consider more aggressive, evidence-based restrictions.
Implications for Future Policy
The researchers are quick to note that while the decline in pregabalin use is a positive development, the work is far from finished. "Use of pregabalin is still far too high," Dr. Cairns told MedPage Today. "There’s a lot of off-label use for conditions with minimal evidence to back that up. And while high-risk use has decreased, we really need to continue to minimize co-use with opioids, which has been shown to increase the risk of death."
For policymakers, the implications are clear:
- Public Awareness Works: The immediate reaction to media reports in 2018 suggests that transparency regarding drug risks is a critical tool in the public health arsenal. When patients and providers are informed of the potential for harm, prescribing patterns shift.
- Regulatory Barriers are Essential: The success of the 2020 dispensing restrictions confirms that administrative barriers—such as requiring authorization for refills or stricter quantity limits—can prevent the normalization of long-term, low-utility use.
- Safety Labeling Matters: The 2021 boxed warnings provided a final, necessary reinforcement. By making the risks visible at the point of care, regulators ensured that every prescription carried a warning of the potential for fatal outcomes.
A Note of Scientific Caution
While the data from the study is compelling, it is not without limitations. Dr. Juurlink emphasized that as an ecological study, it cannot definitively prove causation. Furthermore, poison center calls, while a useful proxy, are an imperfect measure of the true incidence of poisoning. They are subject to variations in reporting practices, public awareness of how to access help, and changes in healthcare seeking behavior.
The researchers also acknowledged that they could only analyze subsidized prescriptions, leaving a gap in data regarding private or out-of-pocket purchases. Despite these caveats, the study remains one of the most rigorous investigations into the impact of regulatory interventions on the use of gabapentinoids.
Conclusion: Towards Safer Pain Management
The story of pregabalin in Australia is a narrative of rapid expansion followed by a calculated, policy-driven correction. It demonstrates that the tide of an epidemic can be turned without necessarily banning a medication, but rather by ensuring that its use is restricted to appropriate clinical indications and that both providers and patients are fully aware of the stakes.
As we move forward, the challenge remains to maintain this momentum. The medical community must continue to interrogate the efficacy of drugs like pregabalin, moving away from a "blockbuster" mentality and toward a more nuanced, evidence-based approach to pain management. For now, the Australian model provides a glimmer of hope: that through education, regulation, and transparency, we can mitigate the risks of the medicines that were intended to heal, but which had become a source of harm.
